RBC Capital on Intellia Therapeutics (NTLA) as Shares Like Over 10%: 'Stock Reaction Overdone'
Tweet Send to a Friend
RBC Capital analyst Luca Issi reiterated an Outperform rating and $150.00 price target on Intellia Therapeutics (NASDAQ: NTLA).The analyst comments ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
